Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2015

View Archived Issues

Sato and Pola Pharma to comarket topical agent for tinea unguium

Nivolumab in esophageal cancer

First-in-class PFKFB4 inhibitor suppresses tumor growth in mice

Serum microRNAs revealed as potential biomarkers for diabetes

Glucokinase regulatory protein may be associated with PCOS

Pfizer acquires Nimenrix and Mencevax from GlaxoSmithKline

FDA accepts Jazz Pharmaceuticals' NDA for defibrotide in hepatic veno-occlusive disease

Progentec and OMRF enter collaboration to develop autoimmune diagnostic tests

Generex to acquire controlling share of Hema Diagnostic Systems

Karolinska Development divests holding in XSpray Microparticles

Kura initiates new phase II trial of tipifarnib in peripheral T-cell lymphoma

PD/PK of topoisomerase inhibitor ACT-387042

Mitsubishi Tanabe licenses rights to Regeneron's fasinumab

Combination of repurposed antidepressants induces autophagy in glioma cells

Otsuka files NDA in Japan for carteolol/latanoprost for glaucoma

FDA awards orphan drug designation to RGX-111 for MPS I

Beijing Hanmi divulges ROR-gamma receptor antagonists

Boehringer Ingelheim discloses SYK inhibitors

NIH awards two grants to OptiKira

Roche and Genentech patent Pim kinase inhibitors

Pfizer introduces DGAT-2 inhibitors

Hinova reports deuterated PARP inhibitors

Allergan adds to esthetics assets with Kythera acquisition

FDA accepts Sandoz BLA for biosimilar etanercept

Biotron releases interim data from phase II study of BIT-225 in HCV

New company Neon Therapeutics to develop neoantigen-based cancer immunotherapies

EMA accepts Ultragenyx's MAA for aceneuramic acid prolonged release

Kaken files application for approval of periodontal regenerative agent KCB-1D

FDA approves Keytruda and companion diagnostic for PD-L1-expressing NSCLC tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...